StreetInsider.com News Articles

Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus

Tue, 30 Jun 2026 16:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026 ("Prospectus") with the securities regulatory authorities in all provinces and territories of Canada.

The Prospectus will allow Theralase® to offer up to C$100 Million of common shares, warrants, subscription receipts, debt securities or any combination thereof

Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus

Tue, 30 Jun 2026 16:30:00 -0400

The Prospectus will allow Theralase® to offer up to C$100 Million of common shares, warrants, subscription receipts, debt securities or any combination thereof

Theralase(R) Lists Warrants on the TSXV

Wed, 03 Jun 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted for listing up to 20,399,050 common share purchase warrants of the Company ("Warrants"), bearing the CUSIP: 88337V142, for trading on the TSXV. The Warrants are expected to commence trading on the TSXV at the open of markets on June 9^th, 2026, under the trading

Theralase(R) Lists Warrants on the TSXV

Wed, 03 Jun 2026 07:00:00 -0400

Theralase(R) Releases Q1 2026 Financial Statements

Fri, 29 May 2026 17:04:00 -0400

Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study

Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's unaudited interim consolidated financial statements for the three-month period ended March 31^st, 2026 ("Financial Statements").

Theralase® will be hosting a conference call on June 9^th at 11:00 am ET, which will include a presentation of the financial and operational results for the

Theralase(R) Releases Q1 2026 Financial Statements

Fri, 29 May 2026 17:04:00 -0400

Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study

Theralase® will be hosting a conference call on June 9^th at 11:00 am ET, which will include a presentation of the financial and operational results for the

Form D THERALASE TECHNOLOGIES

Wed, 27 May 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260527/26555228.html

Form D THERALASE TECHNOLOGIES

Wed, 27 May 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260527/26555228.html

Form D THERALASE TECHNOLOGIES

Wed, 27 May 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260527/26555228.html

Theralase(R) Closes C$4.8 Million Offering

Wed, 20 May 2026 11:06:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering") of 19,166,667 units ("Units") of the Company at a price of C$0.24 per Unit ("Offering Price") for gross proceeds of C$4,600,000; including, the full exercise of the over-allotment option. The Brokered Offering was led by Research Capital Corporation as

Theralase(R) Closes C$4.8 Million Offering

Wed, 20 May 2026 11:06:00 -0400

Theralase(R) Announces $4 Million Brokered LIFE Offering

Tue, 05 May 2026 19:10:00 -0400

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Agent") to act as the sole agent and sole bookrunner on a commercially reasonable "best efforts" agency basis

Theralase(R) Announces $4 Million Brokered LIFE Offering

Tue, 05 May 2026 19:10:00 -0400

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Mon, 04 May 2026 17:22:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period ended December 31^st, 2025 ("Financial Statements").

Theralase® will be hosting a conference call on May 12^th at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal year ending December 31^st, 2025.

To ensure Theralase® has time to

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Mon, 04 May 2026 17:22:00 -0400

To ensure Theralase® has time to

Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study

Mon, 13 Apr 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses has demonstrated a complete response of all animals treated with X-Ray-activated Rutherrin® in a preclinical animal model of Muscle Invasive Bladder Cancer ("MIBC").

Kaplan–Meier survival analysis from the orthotopic MIBC animal study demonstrated that 100% of the animals treated with X-Ray-activated Rutherrin® exhibited a complete response and remained cancer-free at the end of the study; whereas, animals assigned

Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study

Mon, 13 Apr 2026 07:00:00 -0400

Theralase(R) Closes $CAN 2.66 Million Financing

Fri, 10 Apr 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering") of units ("Units") and a Line Of Credit ("LOC").

On closing of the Offering, the Corporation issued an aggregate of 6,404,700 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,665,222.

Each Unit consisted of

Theralase(R) Closes $CAN 2.66 Million Financing

Fri, 10 Apr 2026 07:00:00 -0400

On closing of the Offering, the Corporation issued an aggregate of 6,404,700 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,665,222.

Each Unit consisted of

Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

Tue, 17 Mar 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company, dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce the discovery of an additional Mechanism Of Action ("MOA") as to how Ruvidar® is so effective in the inactivation of the Herpes Simplex Virus ("HSV-1").

Theralase® previously reported that Ruvidar® (TLD-1433) was effective in the inactivation of HSV-1 and was superior to the standard of care treatment Acyclovir. See Figure 1.^1,2,3 (April 10, 2025

Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

Tue, 17 Mar 2026 07:00:00 -0400

Theralase® previously reported that Ruvidar® (TLD-1433) was effective in the inactivation of HSV-1 and was superior to the standard of care treatment Acyclovir. See Figure 1.^1,2,3 (April 10, 2025

Theralase raises $1.1 million in private placement financing

Tue, 10 Mar 2026 07:02:12 -0400

Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) completed a non-brokered private placement offering that raised CAD $1.1 million, the clinical stage pharmaceutical company announced.

The company issued 4,230,770 units at CAD $0.26 per unit. Each unit includes one common share and one warrant that allows the holder to purchase an additional share at CAD $0.36 for five years from the closing date.

Company insiders purchased 100,000 units for CAD $26,000 as part of the offering. The transaction qualifies as a related party transaction under Canadian securities regulations, though the company is exempt from formal valuation requirements and minority shareholder approval.

Theralase stated it

Theralase(R) Closes $1.1 M Non-Brokered Private Placement

Tue, 10 Mar 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units").

On closing, the Corporation issued an aggregate of 4,230,770 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,100,000.

Each Unit consisted of one common share of the Company ("Common Share")

Theralase(R) Closes $1.1 M Non-Brokered Private Placement

Tue, 10 Mar 2026 07:00:00 -0400

On closing, the Corporation issued an aggregate of 4,230,770 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,100,000.

Each Unit consisted of one common share of the Company ("Common Share")

Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer

Mon, 09 Mar 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to present its latest preclinical data demonstrating that X-Ray-activated Rutherrin® is effective in the destruction of Muscle Invasive Bladder Cancer ("MIBC").

In the MIBC preclinical models conducted by the Theralase® research team, Rutherrin® demonstrated an ability to significantly enhance the efficacy of radiation therapy in the destruction of MIBC, supporting its potential as an effective drug for